Published in Gastric Cancer on March 04, 2011
Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer (2013) 1.05
Identification of prognostic factors and surgical indications for metastatic gastric cancer. BMC Cancer (2014) 0.97
Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients. BMC Cancer (2012) 0.91
Survival benefit of palliative gastrectomy in gastric cancer patients with peritoneal metastasis. World J Surg (2012) 0.90
Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat (2014) 0.84
The Value of Palliative Gastrectomy for Gastric Cancer Patients With Intraoperatively Proven Peritoneal Seeding. Medicine (Baltimore) (2015) 0.83
Hepatic metastases from gastric cancer: A surgical perspective. World J Gastroenterol (2015) 0.80
Clinical characteristics and prognostic analysis of Krukenberg tumor. Mol Clin Oncol (2015) 0.75
Palliative Gastrectomy Prolongs Survival of Metastatic Gastric Cancer Patients with Normal Preoperative CEA or CA19-9 Values: A Retrospective Cohort Study. Gastroenterol Res Pract (2016) 0.75
An Unusual Course of Metastatic Gastroesophageal Cancer. Case Rep Oncol Med (2015) 0.75
Distant nodal metastasis: is it always an unresectable disease? Transl Gastroenterol Hepatol (2017) 0.75
Bilateral ovarian metastasis from distal common bile duct carcinoma developing after choledochal cyst excision. Korean J Hepatobiliary Pancreat Surg (2015) 0.75
Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy. Mol Clin Oncol (2016) 0.75
A case of advanced gastric cancer. Gastrointest Cancer Res (2012) 0.75
Modern imaging techniques for preoperative detection of distant metastases in gastric cancer. World J Gastroenterol (2015) 0.75
[Survival advantage of gastrectomy with resection of metastases. In patients with metastasized gastric cancer under chemotherapy]. Chirurg (2012) 0.75
α-Actinin-4 promotes metastasis in gastric cancer. Lab Invest (2017) 0.75
Evaluation of hepatectomy and palliative local treatments for gastric cancer patients with liver metastases: a propensity score matching analysis. Oncotarget (2017) 0.75
Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. J Cancer Res Clin Oncol (2015) 0.75
Third international conference of the European Union Network of Excellence on gastric and esophagogastric junction cancer, Cologne, Germany, June 2012. Gastric Cancer (2014) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol (2006) 7.21
Value of palliative resection in gastric cancer. Br J Surg (2002) 1.90
Defining palliative surgery in patients receiving noncurative resections for gastric cancer. J Am Coll Surg (2004) 1.80
Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg (2005) 1.65
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg (2004) 1.59
Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol (2008) 1.44
Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol (2007) 1.33
Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol (2004) 1.29
Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg (2002) 1.26
Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? World J Surg (2006) 1.23
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg (2004) 1.22
Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol (2008) 1.19
The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost (2009) 1.18
Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology (2001) 1.09
Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol (2007) 1.08
Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol (1998) 1.08
Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg (2009) 1.02
Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg (2007) 1.01
Gastric cancer with metastases to the distant peritoneum: a 20-year surgical experience. Hepatogastroenterology (1998) 1.00
Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? J Surg Oncol (2007) 0.98
Surgical treatment for advanced gastric cancer. Hepatogastroenterology (1996) 0.96
Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent. Ann Surg Oncol (2007) 0.95
Prognostic influence of sub-stages according to pTNM categories in patients with stage IV gastric cancer. J Surg Oncol (2009) 0.88
Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat (2007) 0.85
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol (2010) 5.51
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol (2012) 4.00
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol (2011) 2.89
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.62
Comparative study of laparoscopy-assisted distal gastrectomy and open distal gastrectomy. J Am Coll Surg (2006) 2.23
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98
Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective study. Surg Endosc (2011) 1.85
Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg (2010) 1.84
Learning curve of laparoscopy-assisted distal gastrectomy with systemic lymphadenectomy for early gastric cancer. World J Gastroenterol (2005) 1.83
Comparison of laparoscopy-assisted by conventional open distal gastrectomy and extraperigastric lymph node dissection in early gastric cancer. J Surg Oncol (2005) 1.78
Hippocampal and prefrontal projections to the basal amygdala mediate contextual regulation of fear after extinction. J Neurosci (2011) 1.77
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res (2011) 1.69
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer (2007) 1.68
Comparative study of clinical outcomes between laparoscopy-assisted proximal gastrectomy (LAPG) and laparoscopy-assisted total gastrectomy (LATG) for proximal gastric cancer. Gastric Cancer (2012) 1.65
Laparoscopic resection of nonadrenal retroperitoneal tumors. Arch Surg (2011) 1.61
Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol (2010) 1.54
Analysis of the lymphatic stream to predict sentinel nodes in gastric cancer patients. Ann Surg Oncol (2013) 1.53
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res (2006) 1.53
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer (2010) 1.52
Developing an institutional protocol guideline for laparoscopy-assisted distal gastrectomy. Ann Surg Oncol (2009) 1.51
Effect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees. Eur J Gastroenterol Hepatol (2009) 1.51
Neutralized rocuronium (pH 7.4) before administration prevents injection pain in awake patients: a randomized prospective trial. J Clin Anesth (2007) 1.50
Impaired extinction retention in adolescent rats: effects of D-cycloserine. Neuropsychopharmacology (2010) 1.45
Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol (2006) 1.44
Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging (2005) 1.42
Technical feasibility and safety of laparoscopy-assisted total gastrectomy in gastric cancer: a comparative study with laparoscopy-assisted distal gastrectomy. J Surg Oncol (2009) 1.41
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer (2008) 1.38
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol (2012) 1.37
Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg (2005) 1.37
Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res (2007) 1.35
Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch (2010) 1.34
Laparoscopy-assisted total gastrectomy for gastric cancer: a multicenter retrospective analysis. Surgery (2009) 1.32
Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol Immunol (2007) 1.32
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer (2012) 1.31
Site-specific incorporation of methyl- and acetyl-lysine analogues into recombinant proteins. Angew Chem Int Ed Engl (2008) 1.30
Comparison of short- and long-term outcomes of laparoscopic-assisted total gastrectomy and open total gastrectomy in gastric cancer patients. Surg Endosc (2013) 1.30
Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol (2010) 1.30
Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Laparoscopic total gastrectomy with D2 lymphadenectomy for advanced gastric cancer. World J Surg (2012) 1.26
Cerebral perfusion changes in mesial temporal lobe epilepsy: SPM analysis of ictal and interictal SPECT. Neuroimage (2005) 1.25
Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol (2011) 1.25
Do-not-resuscitate orders for terminal patients with cancer in teaching hospitals of Korea. J Palliat Med (2007) 1.25
Sigmoidorectal intussusception of adenoma of sigmoid colon treated by laparoscopic anterior resection after sponge-on-the-stick-assisted manual reduction. World J Gastroenterol (2006) 1.25
Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol (2010) 1.24
What is the best reconstruction method after distal gastrectomy for gastric cancer? Surg Endosc (2011) 1.23
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett (2008) 1.23
Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol (2010) 1.23
REL1, a homologue of Drosophila dorsal, regulates toll antifungal immune pathway in the female mosquito Aedes aegypti. J Biol Chem (2005) 1.23
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer (2011) 1.22
Actual 3-year survival after laparoscopy-assisted gastrectomy for gastric cancer. Arch Surg (2009) 1.22
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol (2004) 1.22
The impact of a high body mass index on laparoscopy assisted gastrectomy for gastric cancer. Surg Endosc (2009) 1.21
Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast (2011) 1.21
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol (2008) 1.19
Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol (2008) 1.19
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer (2012) 1.19
Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy. Ann Surg Oncol (2008) 1.17
The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer (2009) 1.16
Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck (2010) 1.16
Comparison of complications after laparoscopy-assisted distal gastrectomy and open distal gastrectomy for gastric cancer using the Clavien-Dindo classification. Surg Endosc (2011) 1.12
The role of NF-kappaB factor REL2 in the Aedes aegypti immune response. Insect Biochem Mol Biol (2009) 1.12
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol (2003) 1.12
Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res (2006) 1.12
Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg (2014) 1.12
Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc Natl Acad Sci U S A (2012) 1.11
Sentinel node mapping and skip metastases in patients with early gastric cancer. Ann Surg Oncol (2009) 1.11
Lymphatic mapping and sentinel node biopsy using 99mTc tin colloid in gastric cancer. Ann Surg (2004) 1.11
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer (2008) 1.11
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol (2011) 1.11
Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol (2008) 1.10